4-Aminopyridine (Fampridine) : A new attempt for the symptomatic treatment of multiple sclerosis;4-Aminopyridin (Fampridin) : Ein neuer Ansatz zur symptomatischen Therapie der Multiplen Sklerose

Nervenarzt

Volumn 81, Issue 2, 2010, Pages 203-211

  Husseini, L ^a   Leussink, V I ^a   Kieseier, B C ^a   Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

4 Aminopyridine; Multiple sclerosis; Spasticity; Symptomatic treatment; Uhthoff's phenomenon; Walking distance

Indexed keywords

4 AMINOPYRIDINE; PLACEBO;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INDICATION; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED RELEASE PREPARATION; WALKING DIFFICULTY;

4-AMINOPYRIDINE; ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; POTASSIUM CHANNEL BLOCKERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77249105913     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2902-2     Document Type: Review

References (51)

1. Hemmer B, Nessler S, Zhou D, et al. (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2:201-202
2. Linker R, Kieseier BC (2008) Therapieentscheidungen bei der Multiplen Sklerose - Aktuelles zur Früh- und Eskalationstherapie. Nervenarzt 79:1123-1134
3. Boissy AR, Cohen JA (2007) Multiple sclerosis symptom management. Expert Rev Neurother 7:1213-1222
4. Henze T, Rieckmann P, Toyka KV (2006) Multiple sclerosis therapy consensus group of the german multiple sclerosis society. Symptomatic treatment of multiple sclerosis. Eur Neurol 56:78-105
5. Heesen C, Böhm J, Reich C, et al. (2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14:988-991
6. Goodman AD, Brown TR, Krupp LB, et al. (2009) Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732-738
7. Hayes KC (2004) The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev 10:295-316
8. Bostock H, Sears TA, Sherratt RM (1981) The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 313:301-315
9. Devaux J, Beeton C, Béraud E, Crest M (2004) Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers. Rev Neurol 160:16-27
10. Schmalhofer WA, Bao J, McManus OB, et al. (2002) Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 41:7781-7794
11. Vianna-Jorge R, Suarez-Kurtz G (2004) Potassium channels in T lymphocytes. Drug Mechanisms and Targets 18(5):329-341
12. Rus H, Pardo CA, Hu l, et al. (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102(31):11094-11099
13. Madsen LS, Christophersen P, Olesen PS (2005) Blockade of Ca2+-activated K+ channels in T cells: an option for the treatment of multiple sclerosis? Eur J Immunol 35:1023-1026
14. Hu l, Pennington M, Jiang Q, et al. (2007) Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4 t lymphocytes. Jr Immunol 179:4563-4570
15. Wulf H, Calabresi PA, Allie R, et al. (2003) The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest 111:1701-1713
16. Bever CT, Judge SI (2009) Sustained-release fampridine for multiple sclerosis. Expert Opin Investig Drugs 18:1013-1024
17. Solari A, Uitdehaag B, Giuliani G, et al. (2002) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev CD001330
18. Korenke AR, Rivey MP, Allington DR (2008) Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 42:1458-1465
19. Diemen HA van, Polman CH, Dongen TM van, et al. (1992) The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32:123-130
20. Bever CT Jr, Young D, Anderson PA, et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44:1054-1059
21. Mahad DJ, Trapp BD, Ransohoff RM (2005) Tissue pathology of multiple sclerosis. In: Antel J, Birnbaum G, Hartung HP, Vincent A (eds) Clinical Neuroimmunology, 2nd edn. Oxford Univ, New York, pp 173-183
22. Schwid SR, Goodman AD, Mattson DH, et al. (1997) The measurement of ambulatory impairment in multiple sclerosis. Neurology 49:1419-1424
23. Kragt JJ, Linden FA van der, Nielsen JM, et al. (2006) Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 12:594-598
24. Kaufman M, Moyer D, Norton J (2000) The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 6:286-290
25. Schwid SR, Goodman AD, McDermott MP, et al. (2002) Quantitative functional measures in MS: what is a reliable change? Neurology 58:1294-1296
26. Dobkin BH (2006) Short-distance walking speed and timed walking distance: redundant measures for clinical trials? Neurology 66:584-586
27. Créange A, Serre I, Levasseur M, et al. (2007) Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler 13:220-223
28. Fahey MC, Corben LA, Collins V, et al. (2007) The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia. Neurology 68:705-706
29. Peña F, Tapia R (2000) Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience 101:547-561
30. Kelley BJ, Rodriguez M (2009) Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 23:805-815
31. Burton JM, Bell CM, Walker SE, OConnor PW (2008) 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 71:1833
32. Schwam E (2009) Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med [Epub ahead of print]
33. Goodman AD, Cohen JA, Cross A, et al. (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13:357-368
34. De Cauwer H, De Wolf P, Couvreur F, Mortelmans L (2009) An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 109:40-41
35. Johnson NC, Morgan MW (2006) An unusual case of 4-aminopyridine toxicity. J Emerg Med 30:175-177
36. Goodman AD, Brown TR, Cohen JA, et al. (2008) Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71:1130-1131
37. Hayes KC, Potter PJ, Hsieh JT, et al. (2004) Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 85(1):29-34
38. Velez L, Shirazi F, Goto C, et al. (2003) Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient. Pediatrics 111:82-84
39. Spyker DA, Lynch C, Shabanowitz J, Sinn JA (1980) Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 16:487-497
40. Rossini PM, Pasqualetti P, Pozzilli C, et al. (2001) Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7:354-358
41. Smeets JW, Kunst MW (1995) Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 139:2667-2669
42. Polman CH, Bertelsmann FW, Loenen AC van, Koetsier JC (1994) 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 51:292-296
43. Pickett TA, Enns R (1996) Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 27:382-385
44. Jones RE, Heron JR, Foster DH, et al. (1983) Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 60:353-362
45. Stefoski D, Davis FA, Faut M, Schauf CL (1987) 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21:71-77
46. Davis FA, Stefoski D, Rush J (1990) Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 28:589
47. Stefoski D, Davis FA, Fitzsimmons WE, et al. (1991) 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 41:1344-1348
48. Diemen HA van, Polman CH, Dongen MM van, et al. (1993) 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 116:220-226
49. Smits RC, Emmen HH, Bertelsmann FW, et al. (1994) The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44:1701-1705
50. Schwid SR, Petrie MD, McDermott MP, et al. (1997) Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 48:817-821
51. Goodman AD, Schwid S, Brown T, et al. (2008) Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: a phase 3 trial. World Congress of Treatment and Research in Multiple Sclerosis, Montreal 2008, Program, Poster session 3 - Late Breaking News, P909